We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche needs its pipeline to pick up quick successes, with its big earners are looking at precipitous patent cliffs, and, as the FDA approves its hepatitis A medicine, it looks like it may be delivering.